Research Analysts Issue Forecasts for ABVX FY2029 Earnings

ABIVAX Société Anonyme (NASDAQ:ABVX) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for ABIVAX Société Anonyme in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.92) per share.

Other analysts also recently issued reports about the company. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities restated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $38.67.

ABIVAX Société Anonyme Trading Down 0.7 %

Shares of ABVX stock opened at $5.85 on Thursday. ABIVAX Société Anonyme has a one year low of $5.49 and a one year high of $17.02. The business’s 50 day simple moving average is $7.13 and its 200 day simple moving average is $9.55.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 34.1% in the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock worth $3,105,000 after purchasing an additional 107,750 shares during the last quarter. R Squared Ltd purchased a new position in ABIVAX Société Anonyme during the 4th quarter worth $36,000. GAMMA Investing LLC bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth $29,000. Point72 Asset Management L.P. raised its holdings in shares of ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Finally, Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.